FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553570712> ?p ?o ?g. }

• W2553570712 endingPage "486" @default.
• W2553570712 startingPage "486.1" @default.
• W2553570712 abstract "Objectives The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in clinical remission with a dose reduction treatment regimen of biological therapy in patients with Rheumatoid Arthritis, and to evaluate if the proportion of patients in remission with new regimen dose of treatment is not inferior to patients in remission with standard dose regimen. In our present work, we describe the preliminary results obtained so far. Methods Open, randomized and controlled study of patients in clinical remission (DAS 28 Patients are assigned to two groups randomly. Intervention group: according to a standardized protocol of dose reduction of biological therapies. Control group: according to standard dose regimen. Flare is considered when DAS28>2.6 or SDAI>5 or ACR/EULAR criteria are not fulfilled. Patients are following during after a minimum period of one year and maximum period of 3 years. The frequency of visits is every 12 weeks. Results 58 patients have been included from 14 April 2014 to 11 January 2016. Forty-eight women (82,76%) and 10 men (17,24%) with an average age of 59,34 ± 11,28 years. Twenty-nine in standard regimen dose and 29 patients in dose reduction regimen. None of the patients had tender or swollen joints at the beginning. At baseline, ESR and CRP values were 16,84 mm/1hour y 0,22 mg/dl respectively. DAS 28-ESR value was 1,84 ± 0.72 and DAS28-CRP was 1.34 ± 0.26. Rheumatoid Factor is positive in 79.31%. Forty-one patients have erosive disease. Seventeen patients have presented a flare: 24,13% in control group and 34,48% in intervention group without statistical signification (p=0.5640). The characteristics of the patients are described in table 1. Statistic differences were not found. Conclusions Preliminary results show that dose reduction of biological therapies with a standardized protocol it does not seem to increase reactivation risk of disease activity. Disclosure of Interest None declared" @default.
• W2553570712 created "2016-11-30" @default.
• W2553570712 creator A5004606698 @default.
• W2553570712 creator A5007480735 @default.
• W2553570712 creator A5017527909 @default.
• W2553570712 creator A5019811024 @default.
• W2553570712 creator A5022039092 @default.
• W2553570712 creator A5047558519 @default.
• W2553570712 creator A5047606143 @default.
• W2553570712 creator A5049872450 @default.
• W2553570712 creator A5083304899 @default.
• W2553570712 creator A5087305197 @default.
• W2553570712 creator A5091714286 @default.
• W2553570712 date "2016-06-01" @default.
• W2553570712 modified "2023-10-13" @default.
• W2553570712 title "FRI0158 Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. The Optibio Study" @default.
• W2553570712 doi "https://doi.org/10.1136/annrheumdis-2016-eular.4839" @default.
• W2553570712 hasPublicationYear "2016" @default.
• W2553570712 type Work @default.
• W2553570712 sameAs 2553570712 @default.
• W2553570712 citedByCount "1" @default.
• W2553570712 countsByYear W25535707122022 @default.
• W2553570712 crossrefType "journal-article" @default.
• W2553570712 hasAuthorship W2553570712A5004606698 @default.
• W2553570712 hasAuthorship W2553570712A5007480735 @default.
• W2553570712 hasAuthorship W2553570712A5017527909 @default.
• W2553570712 hasAuthorship W2553570712A5019811024 @default.
• W2553570712 hasAuthorship W2553570712A5022039092 @default.
• W2553570712 hasAuthorship W2553570712A5047558519 @default.
• W2553570712 hasAuthorship W2553570712A5047606143 @default.
• W2553570712 hasAuthorship W2553570712A5049872450 @default.
• W2553570712 hasAuthorship W2553570712A5083304899 @default.
• W2553570712 hasAuthorship W2553570712A5087305197 @default.
• W2553570712 hasAuthorship W2553570712A5091714286 @default.
• W2553570712 hasConcept C126322002 @default.
• W2553570712 hasConcept C141071460 @default.
• W2553570712 hasConcept C168563851 @default.
• W2553570712 hasConcept C203092338 @default.
• W2553570712 hasConcept C2777575956 @default.
• W2553570712 hasConcept C2779384505 @default.
• W2553570712 hasConcept C2781413609 @default.
• W2553570712 hasConcept C535046627 @default.
• W2553570712 hasConcept C71924100 @default.
• W2553570712 hasConceptScore W2553570712C126322002 @default.
• W2553570712 hasConceptScore W2553570712C141071460 @default.
• W2553570712 hasConceptScore W2553570712C168563851 @default.
• W2553570712 hasConceptScore W2553570712C203092338 @default.
• W2553570712 hasConceptScore W2553570712C2777575956 @default.
• W2553570712 hasConceptScore W2553570712C2779384505 @default.
• W2553570712 hasConceptScore W2553570712C2781413609 @default.
• W2553570712 hasConceptScore W2553570712C535046627 @default.
• W2553570712 hasConceptScore W2553570712C71924100 @default.
• W2553570712 hasIssue "Suppl 2" @default.
• W2553570712 hasLocation W25535707121 @default.
• W2553570712 hasOpenAccess W2553570712 @default.
• W2553570712 hasPrimaryLocation W25535707121 @default.
• W2553570712 hasVolume "75" @default.
• W2553570712 isParatext "false" @default.
• W2553570712 isRetracted "false" @default.
• W2553570712 magId "2553570712" @default.
• W2553570712 workType "article" @default.